Effect of agonists of adenosine receptors on inflammatory markers in human Muller cells

Current Science

Volumn 106, Issue 4, 2014, Pages 582-586

  Kumar, Selva ^a   Safi, Sher Zaman ^a   Qvist, Rajes ^a   Ismail, Ikram Shah ^a  

^a UNIVERSITY OF MALAYA   (Malaysia)

Author keywords

Adenosine receptors; Agonists; Diabetic retinopathy; Inflammatory markers; MIO M1 cells

Indexed keywords

EID: 84894502878     PISSN: 00113891     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Williams, R., Airey, M., Baxter, H., Forrester, J., Kennedy-Martin, T. and Girach, A., Epidemiology of diabetic retinopathy and macular oedema: a systematic review. Eye (London), 2004, 18, 963-983.
2. Antonetti, D. A. et al., Diabetic Retinopathy Center Group, Diabetic retinopathy: seeing beyond glucose-induced microvascular disease. Diabetes, 2006, 55, 2401-2411.
3. Johnny, T. and Timothy, S. K., Inflammation in diabetic retinopathy. Prog. Retinal Eye Res., 2011, 30, 343-358.
4. Gregory, I. L., Diabetic retinopathy: role of inflammation and potential therapies for inflammation. World J. Diabetes, 2010, 1, 12-18.
5. Wiley, L. A., Rupp, G. R. and Steinle, J. J., Sympathetic innervation regulates basement membrane thickening and pericyte number in rat retina. Invest. Ophthalmol. Vis. Sci., 2005, 46, 744-748.
6. Walker, R. J. and Steinle, J. J., Role of β -adrenergic receptors in inflammatory marker expression in Muller cells. Invest. Ophthalmol. Vis. Sci., 2007, 48, 5276-5281
7. Zhang, W., Liu, H., Al-Shabrawey, M., Caldwell, R. W. and Caldwell, R. B., Inflammation and diabetic retinal microvascular complications. J. Cardiovasc. Dis. Res., 2011, 2, 96-103.
8. Barreiro, O., Martin, P., Gonzalez-Amaro, R. and Sanchez-Madrid, F., Molecular cues guiding inflammatory responses. Cardiovasc. Res., 2010, 86, 174-182.
9. Abu el Asrar, A. M. et al., Cytokines in the vitreous fluid and serum of patients with proliferative diabetic retinopathy. Am. J. Opthalmal., 1992, 114, 731-736.
10. Yuuki, T. et al., Inflammatory cytokines in the vitreous fluid and serum of patients with diabetic vitreoretinopathy. J. Diabetes Complications, 2001, 15, 257-259.
11. Kowluru, R. A. and Odenbach, S., Role of interleukin-1β in the pathogenesis of diabetic retinopathy. Br. J. Ophthalmol., 2004, 88, 1343-1347.
12. Joussen, A. M. et al., Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression. FASEB J., 2002, 16, 438-440.
13. Limb, G. A., Chignell, A. H., Green, W., LeRoy, F. and Dumonde, D. C., Distribution of TNF alpha and its reactive vascular adhesion molecules in fibrovascular membranes of proliferative diabetic retinopathy. Br. J. Ophthalmol., 1996, 80, 168-173.
14. Demircan, N., Safran, B. G., Soylu, M., Ozcan, A. A. and Sismaz, S., Determination of vitreous interleukin-1 (IL-1) and tumour necrosis factor (TNF) levels in proliferative diabetic retinopathy. Eye (London), 2006, 20, 1366-1369.
15. Yunpeng, D. U., Sarthy, V. P. and Kern, T. S., Interactions between No and Cox pathoways in retinal cells exposed to elevated glucose and retina of the diabetic rats. Am. J. Physiol., 2004, 287, 735-741.
16. Zong, H., Ward, M., Madden, A., Yong, P. H., Limb, G. A., Curtis, T. M. and Stitt, A. W., Hyperglycemia-induced pro-inflammatory responses by retinal Müller glia are regulated by the receptor for advanced glycation end-products (RAGE). Diabetologia, 2010, 53, 2656-2666.
17. Bringmann, A. et al., Muller cells in the healthy and diseased retina. Prog. Retinal Eye Res., 2006, 25, 397-424.
18. Mizutani, M., Gerhardinger, C. and Lorenzi, M., Muller cells change in human diabetic retinopathy. Diabetes, 1998, 47, 445-449.
19. Newman, E. and Reichenbach, A., The Muller cell: a functional element of the retina. Trends Neurosci., 1996, 19, 307-312.
20. Hasko, G. and Cronstein, B. N., Adenosine: an endogenous regulator of innate immunity. Trends Immunol., 2004, 25, 33-39.
21. Gebremehdin, D., Weinberger, B., Lourim, D. and Harder, D. R., Adenosine can mediate its action through generation of reactive oxygen species. J. Cereb. Blood Flow Metab., 2010, 30, 1777-1790.
22. Fredholm, B. B. and Ijzerman, A. P., International union of pharmacology XXV nomenclature and classification of adenosine receptors. Pharmacol. Rev., 2001, 53, 527-552.
23. Morello, S., Sorrentino, R. and Pinto, A., Adenosine A2a receptor agonists as regulators of inflammation: pharmacology and therapeutic opportunities. J. Receptor, Ligand Channel Res., 2009, 2, 11-17.
24. Merighi, S. et al., A glance at adenosine receptors: novel target for antitumor therapy. Pharmacol. Thera., 2003, 100, 31-48.
25. Erb, L., Liao, Z., Seye, C. I. and Weisman, G. A., P2 receptors: intracellular signaling. Eur. J. Physiol., 2006, 452, 552-562.
26. Limb, G. A., Salt, T. E., Munro, P. M., Moss, S. E. and Khaw, P. T., In vitro characterization of a spontaneously immortalized human Muller cell line (MIO-M1). Invest. Ophthalmol. Vis. Sci., 2002, 43, 864-869.
27. Castillo, C., Albasanz, J., Fernandez, M. and Martin, M., Endogenous expression of adenosine receptors in rat C6 glioma cells. Neurochem. Res., 2007, 32, 1056-1070.
28. Hollborn, M., Jahn, K., Limb, G. A., Kohen, L., Wiedemann, P. and Bringmann, A., Characterization of the basic fibroblast growth factor-evoked proliferation of the human Muller cell line, MIO-M1. Graef. Arch. Clin. Exp. Opthalmol., 2004, 242, 414-422.
29. Van Hecke, M. V. et al., Inflammation and endothelial dysfunction are associated with retinopathy: the Hoorn study. Diabetologia, 2005, 48, 1300-1306.
30. Sijkerman, A. M. W. et al., Endothelia l dysfunction and low grade in inflammation and the progression of retinopathy in type 2 diabetes. Diabetic Med., 2007, 24, 969-976.
31. Navarro, J. F. and Mora, C., Role of inflammation in diabetic complications. Nephrol. Dial. Transplant., 2005, 20, 2601-2604.
32. Tezel, G. and Wax, G. B., Increased production of tumor necrosis factor-α by glial cells exposed to simulated ischemia or elevated hydrostatic pressure induces apoptosis in cocultured retinal ganglion cells. J. Neurosci., 2000, 20, 8693-8700.
33. Liou, G. I., Ahmad, S., Naime, M. and Fatteh, N., Role of adenosine in diabetic retinopathy. J. Ocul. Biol. Dis. Inf., 2011, 4, 19-24.
34. 2A)AR) as a therapeutic target in diabetic retinopathy. Am. J. Pathol., 2011, 178, 2136-2145.
35. Klinger, M., Freissmuth, M. and Nanoff, C., Adenosine receptors: G protein-mediated signalling and the role of accessory proteins. Cell. Signal., 2002, 14, 99-108.
36. 2B receptors. Pharmacol. Rev., 1997, 49, 381-402.
37. Rosaria, V. et al., Medicinal chemistry and pharmacology of A2B adenosine receptors. Curr. Top. Med. Chem., 2003, 3, 427-443.
38. Vincent, J. A. and Mohr, S., Inhibition of caspase-1/interleukin-1 signaling prevents degeneration of retinal capillaries in diabetes and galactosemia. Diabetes, 2007, 56, 224-230.
39. Krady, J. K. et al., Minocycline reduces proinflammatory cytokine expression, microglial activation, and caspase-3 activation in a rodent model of diabetic retinopathy. Diabetes, 2005, 54, 1559-1565.
40. Dasu, M. R., Devaraj, S. and Jialal, I., High glucose induces IL-1β expression in human monocytes: mechanistic insights. Am. J. Physiol. Endocrinol. Metab., 2007, 293, E337-E346.
41. Liu, Y., Costa, B. M. and Gerhardinger, C., IL-1β is upregulated in the diabetic retina and retinal vessels: cell-specific effect of high glucose and IL-1β autostimulation. PLoS One, 2012, 7, e36949.
42. Asakawa, H., Miyagawa, J., Hanafusa, T., Kuwajima, M. and Matsuzawa, Y., High glucose and hyperosmolarity increase secretion of interleukin-1β in cultured human aortic endothelial cells. J. Diabetes Complications, 1997, 11, 176-179.
43. Chen, W., Jump, D. B., Grant, M. B., Esselman, W. J. and Busik, J. V., Dyslipidemia, but not hyperglycemia, induces inflammatory adhesion molecules in human retinal vascular endothelial cells. Invest. Ophthalmol. Vis. Sci., 2003, 44, 5016-5022.